Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data
Heidi J. Einolf, Ping Zhao(Beijing Obstetrics and Gynecology Hospital), Jashvant D. Unadkat(University of Washington), R. Scott Obach(Pfizer (United States)), Odette A. Fahmi(Pfizer (United States)), J Silva(Johnson & Johnson (United States)), Mohamad Shebley(AbbVie (United States)), Michael Sinz(Rutgers, The State University of New Jersey), L Zhang(United States Food and Drug Administration), Christopher R. Gibson(United States Military Academy), L Chen(GlaxoSmithKline (United States))
Cited by 93
Related Papers
Prevention of Neural-Tube Defects with Folic Acid in China
|New England Journal of Medicine|1999|1.3k
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
|The AAPS Journal|2014|646
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
Emerging Transporters of Clinical Importance: An Update From the International Transporter Consortium
|Clinical Pharmacology & Therapeutics|2013|346
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
|Chemical Research in Toxicology|1998|312